Literature DB >> 10795096

[Projection of the number of multiple sclerosis patients in Germany].

T Hein1, W Hopfenmüller.   

Abstract

For determining the prevalence of multiple sclerosis (MS) in Germany, the outcomes of several epidemiological studies are available. If these rates are transferred to Germany as a whole, figures result of 67,000 to 138,000 MS patients in all. The differing prevalence rates may be caused by various problems in finding patients, the epidemiological area, and different population structures. To avoid these difficulties, a new approach for calculating the number of patients with diagnosed MS was chosen based on representative samples taken from the groups of physicians involved in MS treatment. The disadvantage of this approach is that it does not allow any questioning of the diagnosis. Projecting the results in this way and their subsequent compilation--taking "double treatments" into consideration--showed a total of 122,000 patients with diagnosed multiple sclerosis in Germany. This figure corresponds to a prevalence rate of 149.1 per 100,000 inhabitants and is within the range found by Poser et al. [19]: 127 per 100,000 excluding the diagnostic category "possible multiple sclerosis" and 170 per 100,000 including it.

Entities:  

Mesh:

Year:  2000        PMID: 10795096     DOI: 10.1007/s001150050559

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  20 in total

1.  [MS registry in Germany--design and first results of the pilot phase].

Authors:  P Flachenecker; U K Zettl; U Götze; J Haas; S Schimrigk; W Elias; M Pette; M Eulitz; M Hennig; J Bertram; R Hollweck; A Neiss; M Daumer; D Pitschnau-Michel; P Rieckmann
Journal:  Nervenarzt       Date:  2005-08       Impact factor: 1.214

2.  [Epidemiology of multiple sclerosis in Germany: regional differences and drug prescription in the claims data of the statutory health insurance].

Authors:  G Petersen; R Wittmann; V Arndt; D Göpffarth
Journal:  Nervenarzt       Date:  2014-08       Impact factor: 1.214

Review 3.  [Vitamin D and multiple sclerosis : the role for risk of disease and treatment].

Authors:  A Döring; F Paul; J Dörr
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

4.  [Medical care of patients with spasticity following stroke : Evaluation of the treatment situation in Germany with focus on the use of botulinum toxin].

Authors:  L Kerkemeyer; G Lux; A Walendzik; J Wasem; A Neumann
Journal:  Nervenarzt       Date:  2017-08       Impact factor: 1.214

Review 5.  Epidemiology of neuroimmunological diseases.

Authors:  Peter Flachenecker
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

6.  Cluster headache: clinical features and therapeutic options.

Authors:  Charly Gaul; Hans-Christoph Diener; Oliver M Müller
Journal:  Dtsch Arztebl Int       Date:  2011-08-19       Impact factor: 5.594

7.  [Simultaneous presentation of amyotrophic lateral sclerosis and multiple sclerosis].

Authors:  B Machner; S Gottschalk; H Kimmig; C Helmchen
Journal:  Nervenarzt       Date:  2007-12       Impact factor: 1.214

8.  [Pharmaceutical prescription for multiple sclerosis : evaluation of pharmaceutical consumption at private health insurance].

Authors:  F Wild
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

9.  Treatment of multiple sclerosis in Germany: an analysis based on claims data of more than 30,000 patients.

Authors:  Roland Windt; Gerd Glaeske; Falk Hoffmann
Journal:  Int J Clin Pharm       Date:  2013-10-09

Review 10.  [Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].

Authors:  H-P Hartung; J Haas; M Meergans; F Tracik; S Ortler
Journal:  Nervenarzt       Date:  2013-06       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.